Published in Oncogene on April 29, 2013
Survivin - The inconvenient IAP. Semin Cell Dev Biol (2015) 1.04
Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells. Oncotarget (2015) 0.97
Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. Oncotarget (2014) 0.94
AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget (2015) 0.93
Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer (2015) 0.90
CDC20 maintains tumor initiating cells. Oncotarget (2015) 0.90
Protein expression of eIF4E and integrin αvβ6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction. Cell Biosci (2014) 0.90
Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway. J Transl Med (2014) 0.89
miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition. Cell Death Dis (2014) 0.88
Role of IGF2BP3 in trophoblast cell invasion and migration. Cell Death Dis (2014) 0.87
Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway. ScientificWorldJournal (2014) 0.82
The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications. Oncotarget (2016) 0.81
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo. Int J Oncol (2014) 0.80
Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med (2016) 0.80
New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell Microenviron (2015) 0.79
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol (2014) 0.79
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer (2016) 0.79
RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget (2014) 0.78
Role of H-Ras/ERK signaling in carbon nanotube-induced neoplastic-like transformation of human mesothelial cells. Front Physiol (2014) 0.77
Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma. Oncotarget (2015) 0.77
FUSION-Guided Hypothesis Development Leads to the Identification of N⁶,N⁶-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor. Mar Drugs (2017) 0.76
p70 S6-kinase mediates the cooperation between Akt1 and Mek1 pathways in fibroblast-mediated extracellular matrix remodeling. Biochim Biophys Acta (2015) 0.76
MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer (2017) 0.76
So-Cheong-Ryong-Tang induces apoptosis through activation of the intrinsic and extrinsic apoptosis pathways, and inhibition of the PI3K/Akt signaling pathway in non-small-cell lung cancer A549 cells. BMC Complement Altern Med (2015) 0.76
E2F-1 overexpression inhibits human gastric cancer MGC-803 cell growth in vivo. World J Gastroenterol (2015) 0.76
4E-BP1 as an oncotarget. Aging (Albany NY) (2015) 0.76
Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer. Oncotarget (2016) 0.75
The clinicopathological significance of SPC18 in colorectal cancer: SPC18 participates in tumor progression. Cancer Sci (2016) 0.75
Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal (2017) 0.75
TGF-β signal rewiring sustains epithelial-mesenchymal transition of circulating tumor cells in prostate cancer xenograft hosts. Oncotarget (2016) 0.75
Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation. PLoS One (2015) 0.75
Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin A. Medicine (Baltimore) (2015) 0.75
Ubiquitin-like protein FAT10 promotes bladder cancer progression by stabilizing survivin. Oncotarget (2016) 0.75
Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells. Oncol Lett (2016) 0.75
Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures. Oncol Lett (2015) 0.75
Efficacy comparison of lyophilised black raspberries and combination of celecoxib and PBIT in prevention of carcinogen-induced oesophageal cancer in rats. J Funct Foods (2016) 0.75
Genomics alterations of metastatic and primary tissues across 15 cancer types. Sci Rep (2017) 0.75
Glycans as Regulatory Elements of the Insulin/IGF System: Impact in Cancer Progression. Int J Mol Sci (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Global quantification of mammalian gene expression control. Nature (2011) 22.36
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell (2009) 14.51
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature (1994) 9.30
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer (2004) 6.07
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
mTOR, translation initiation and cancer. Oncogene (2006) 4.68
Translational control in cancer. Nat Rev Cancer (2010) 4.59
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res (2009) 4.50
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One (2008) 4.12
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res (2011) 3.12
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
IAP regulation of metastasis. Cancer Cell (2010) 2.47
Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res (2010) 1.77
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer (2009) 1.44
Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene (1999) 1.44
An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer (2011) 1.40
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem (2002) 1.37
Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res (2012) 1.31
Mechanisms governing the control of mRNA translation. Phys Biol (2010) 1.27
mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med (2012) 1.21
Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res (2012) 1.20
Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res (2011) 1.16
4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol (2000) 1.11
Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One (2009) 1.09
Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer (2011) 1.08
Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev (2001) 1.07
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol (2011) 1.06
Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys (2010) 1.04
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res (2011) 0.88